PDS Biotechnology Corporation
PDSB
$1.26
$0.021.61%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 13.76M | 13.87M | 14.56M | 15.10M | 15.28M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 36.32M | 39.37M | 39.71M | 43.72M | 43.05M |
Operating Income | -36.32M | -39.37M | -39.71M | -43.72M | -43.05M |
Income Before Tax | -38.48M | -41.43M | -41.55M | -45.29M | -44.35M |
Income Tax Expenses | -869.20K | -869.20K | -869.20K | -1.41M | -1.41M |
Earnings from Continuing Operations | -37.61 | -40.56 | -40.68 | -43.89 | -42.94 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -37.61M | -40.56M | -40.68M | -43.89M | -42.94M |
EBIT | -36.32M | -39.37M | -39.71M | -43.72M | -43.05M |
EBITDA | -36.26M | -39.31M | -39.65M | -43.66M | -42.99M |
EPS Basic | -1.04 | -1.17 | -1.23 | -1.37 | -1.39 |
Normalized Basic EPS | -0.66 | -0.74 | -0.78 | -0.89 | -0.90 |
EPS Diluted | -1.04 | -1.17 | -1.23 | -1.37 | -1.39 |
Normalized Diluted EPS | -0.66 | -0.74 | -0.78 | -0.89 | -0.90 |
Average Basic Shares Outstanding | 145.80M | 139.98M | 134.08M | 128.19M | 123.80M |
Average Diluted Shares Outstanding | 145.80M | 139.98M | 134.08M | 128.19M | 123.80M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |